Table1. Characteristics of the subjects.
| Variables | Total (n = 809) | Patients receiving ULT (n = 755) | |||
|---|---|---|---|---|---|
| ULT adherence ≥ 80% (n = 673) | ULT adherence < 80% (n = 82) | P value | |||
| Age, mean ± SD, yr | 53.5 ± 13.7 | 54.2 ± 13.5 | 49.1 ± 13.4 | 0.001 | |
| Male | 789 (97.6) | 656 (97.6) | 81 (98.8) | 1.000 | |
| BMI, mean ± SD, kg/m2 | 26.4 ± 3.7 | 26.3 ± 3.8 | 26.6 ± 3.1 | 0.333 | |
| Disease duration, mean ± SD, yr | 8.2 ± 7.9 | 8.4 ± 7.9 | 6.1 ± 6.4 | 0.011 | |
| Comorbidities | 548 (67.7) | 466 (69.2) | 49 (59.8) | 0.082 | |
| Urinary stone | 57 (7.0) | 48 (7.1) | 7 (8.5) | 0.644 | |
| Diabetes mellitus | 97 (12.0) | 86 (12.8) | 7 (8.5) | 0.270 | |
| Hypertension | 352 (43.5) | 305 (45.3) | 27 (32.9) | 0.033 | |
| Dyslipidemia | 220 (27.2) | 192 (28.5) | 16 (19.5) | 0.084 | |
| Cardiovascular diseasea | 96 (11.9) | 85 (12.6) | 6 (7.3) | 0.163 | |
| Cerebrovascular disease | 21 (2.6) | 17 (2.5) | 1 (1.2) | 0.710 | |
| Renal dysfunction | 87 (10.8) | 75 (11.1) | 7 (8.5) | 0.474 | |
| Gout attacks in the past year | < 0.001 | ||||
| None | 342 (42.3) | 311 (46.2) | 20 (24.4) | ||
| 1–3 | 359 (44.4) | 271 (40.3) | 51 (62.2) | ||
| ≥ 4 | 108 (13.3) | 91 (13.5) | 11 (13.4) | ||
| Current use of ULT | 755 (94.5) | - | - | - | |
| Allopurinol | 138 (18.3) | 126 (18.7) | 12 (14.6) | 0.366 | |
| Febuxostat | 313 (41.5) | 283 (42.1) | 30 (36.6) | 0.343 | |
| Benzbromarone | 15 (2.0) | 15 (2.2) | 0 (0) | 0.392 | |
| Do not know | 258 (34.2) | 223 (33.1) | 35 (42.7) | 0.108 | |
| Use of alternative treatments | 131 (16.4) | 112 (16.8) | 13 (16.5) | 0.940 | |
| Natural supplements | 117 (14.7) | 101 (15.2) | 12 (15.4) | 0.968 | |
| Herbal remedies | 15 (1.9) | 13 (2.0) | 0 (0) | 0.381 | |
Data are presented as number (%).
ULT = urate lowering therapy, SD = standard deviation, BMI = body mass index.
aIncludes ischemic heart disease, myocardial infarction, arrythmia, congestive heart failure.